Management of Orthostatic Hypotension

Definition and Diagnostic Criteria

• Orthostatic hypotension is defined as a sustained drop in systolic blood pressure ≥ 20 mm Hg or diastolic blood pressure ≥ 10 mm Hg within 3 minutes of standing from the supine position (American College of Cardiology; American Heart Association) [1][2].

Etiology

Neurogenic (Autonomic) Causes

• Primary autonomic failure syndromes—pure autonomic failure, multiple system atrophy, Parkinson’s disease, and dementia with Lewy bodies—are recognized precipitants (American College of Cardiology) 1.
• Secondary autonomic failure: diabetes mellitus contributes to orthostatic hypotension in 10‑30 % of elderly patients with diabetes (Endocrine Practice) 4.
• Transthyretin (ATTR) amyloidosis with polyneuropathy is a specific cause of neurogenic orthostatic hypotension (Journal of the American College of Cardiology) 5.
• Additional secondary neurogenic causes include spinal cord injury, autoimmune autonomic neuropathy, paraneoplastic autonomic neuropathy, and chronic kidney disease (American College of Cardiology) 1.

Non‑Neurogenic Causes

• Medication‑induced orthostatic hypotension is the most common reversible factor; implicated agents include diuretics, vasodilators, venodilators, negative chronotropes, and sedatives (Circulation) 2.
• Tricyclic antidepressants, phenothiazines, and α‑adrenoreceptor antagonists also precipitate orthostatic drops (Endocrine Practice) 4.
• The prevalence of medication‑related syncope rises markedly with advancing age (Circulation) 2.

First‑Line Non‑Pharmacologic Management (Class I)

• Discontinue or reduce aggravating medications as the initial step (Class IIa) (Circulation; Praxis) [2][3].
• Review specific drug classes—diuretics, vasodilators, psychotropic agents, and α‑blockers—and adjust under close supervision because of potential supine hypertension or arrhythmias (Circulation) 2.
• Do not simply de‑intensify antihypertensive therapy in patients with co‑existing hypertension; instead, switch to agents that do not exacerbate orthostatic drops (Praxis) 3.
• Volume expansion: encourage 2–3 L of fluid intake daily (Praxis) 3; add ≈10 g of sodium chloride per day when not contraindicated by heart failure (Praxis) 3.
• A rapid 500 mL water bolus acutely improves orthostatic tolerance and mitigates post‑prandial hypotension (Circulation; Praxis) [2][3].
• Positional strategies: elevate the head of the bed ~10° to reduce nocturnal polyuria (Endocrine Practice; Praxis) [4][3]; avoid abrupt postural changes and use staged movements (Endocrine Practice) 4; limit large carbohydrate‑rich meals (Endocrine Practice) 4.
• Physical counter‑pressure maneuvers—leg crossing, squatting, stooping, and muscle tensing—should be taught to patients with warning symptoms (Endocrine Practice; Praxis) [4][3].
• Compression garments (knee‑ or thigh‑high elastic stockings and abdominal binders) limit venous pooling and provide benefit without drug‑related adverse effects (Journal of the American College of Cardiology; Endocrine Practice; Praxis) [5][4]3.

Pharmacologic Therapy (When Symptoms Persist)

First‑Line Agents

• Midodrine – FDA‑approved α₁‑adrenergic agonist producing arteriolar and venoconstriction; Level A evidence (Praxis) 3.

  • Typical dosing: start low and titrate up to 10 mg 2–4 times daily (Praxis) 3.
  • Administer the first dose before arising; avoid dosing several hours before planned recumbency (Praxis) 3.
  • Common adverse effects: pilomotor reactions, pruritus, supine hypertension, bradycardia, gastrointestinal symptoms, urinary retention (Praxis) 3.

• Fludrocortisone – Mineralocorticoid that promotes sodium retention and modest vasoconstriction; Level B evidence (Praxis) 3.

  • Dosing: initiate 0.05–0.1 mg daily, titrate to 0.1–0.3 mg as needed (Praxis) 3.
  • Adverse effects include supine hypertension, hypokalemia, peripheral edema, and risk of congestive heart failure (Praxis) 3.
  • Poor tolerance is noted in patients with cardiac involvement or restrictive physiology (Journal of the American College of Cardiology) 5.

• Combination therapy (midodrine + fludrocortisone) is recommended for patients not responding to monotherapy (Praxis) 3 (Class IIa).

Second‑Line Options

• Droxidopa – FDA‑approved norepinephrine precursor for neurogenic orthostatic hypotension; Level A evidence (Journal of the American College of Cardiology; Praxis) [5][3].

  • Dosing is individualized; caution in patients with cardiac involvement due to tolerability concerns (Journal of the American College of Cardiology) 5.

• Pyridostigmine – Provides symptomatic relief without fluid retention or supine hypertension; better tolerated in heart‑failure patients (Journal of the American College of Cardiology) 5.

Targeted Therapies for Specific Situations

• Anemia‑related orthostatic hypotension – Consider erythropoietin (25–75 U/kg SC/IV three times weekly) when hemoglobin < 11 g/dL; raises both supine and upright pressures independent of hematocrit change (Praxis) 3.
• Nocturnal polyuria – Desmopressin acetate reduces nocturnal urine output and improves morning orthostatic symptoms (Praxis) 3.
• Post‑prandial hypotension – Caffeine attenuates symptoms via vasoconstrictive effects (Praxis) 3.

Monitoring, Goals, and Special Populations

• The primary therapeutic goal is to lessen postural symptoms and improve quality of life, not to normalize blood pressure (Praxis) 3.
• Treatment is indicated only when orthostatic hypotension is symptomatic (Praxis) 3.
• Supine hypertension risk must be balanced against standing blood‑pressure benefit (Level C) (Praxis) 3; regular monitoring for supine hypertension is advised when using midodrine or fludrocortisone (Praxis) 3.
• Therapy adjustments should be guided by symptom relief rather than absolute blood‑pressure targets (Praxis) 3.

ATTR Amyloidosis with Polyneuropathy

• In this subgroup, most pharmacologic agents (except pyridostigmine) are often poorly tolerated due to cardiac involvement and restrictive physiology (Journal of the American College of Cardiology) 5.
• Compression garments are preferred as they avoid drug‑related risks (Journal of the American College of Cardiology) 5.
• Tricyclic antidepressants for neuropathic pain may exacerbate orthostatic hypotension and should be avoided (Journal of the American College of Cardiology) 5.